



GlaxoSmithKline
Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi – 74000,
Pakistan

T +92 21 111 475 725

March 14, 2023

The Commissioner (Enf.)
Securities & Exchange Commission of Pakistan
7th Floor, NIC Building, Jinnah Avenue, Blue Area
Islamabad

Dear Sir,

**Subject: Extension in the time for Holding of Annual General Meeting
u/s 132 of the Companies Act, 2017, for the Year ended December 31, 2022**

We are enclosing herewith the following documents for permission of extension in time for holding of Annual General Meeting:-

1. Application for extension in the period for holding of Annual General Meeting
2. An affidavit duly signed by the Company Secretary and attested by the Oath Commissioner
3. A paid Challan of Rs.15,025/- being fee for Extension of Annual General Meeting
4. Copies of Audited Accounts for the years ended December 31, 2021, 2020, 2019

You are requested to kindly acknowledge receipt and allow us an extension of 30 days in the holding of Annual General Meeting for the year ended 31 December, 2022.

Thanking you,

Yours faithfully,

For and on behalf of
GlaxoSmithKline Pakistan Limited


Ms. Mehar-e-daraksha Ameer
Company Secretary



March 15, 2023

GlaxoSmithKline
Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi – 74000,
Pakistan

T +92 21 111 475 725

Mr. Irfan Afzal
Joint Director(CSD)
Enforcement Department,
Securities & Exchange Commission of Pakistan,
7th Floor, NIC Building, Jinnah Avenue, Blue Area,
Islamabad.

Dear Sir,

Subject: Application for Extension of 30 days in Holding of Annual General Meeting u/s 132 of the Companies Act, 2017, for the Year ended December 31, 2022

We are writing to the Honourable Commission for granting extension of 30 days' time to GlaxoSmithKline Pakistan Limited for holding its Annual General Meeting for the year ended December 31, 2022, and to present therein audited financial Statement for the same financial year. This application is made under section 132(1), section 223(2) of the Companies Act, 2017.

The required particulars are as under:

- i. Company's Registration Number is **0000061**
- ii. Last Annual General Meeting was the 75th Annual General Meeting, held on April 25, 2022 for the financial year ended December 31, 2021.
- iii. The Audited financial statements presented in the 75th Annual General Meeting were for the financial year ended on December 31, 2021.
- iv. The date up to which the Annual General Meeting is required to be held under the rule is April 30, 2023 and the audited financial statements required to be presented are of the financial year ended on December 31, 2022.

Reason for extension

The reason which has compelled the Company to seek an extension is given below:

1. The Annual General Meeting (AGM) of GlaxoSmithKline Pakistan Limited (GSKP) is scheduled to be held on April 27, 2023 for the financial year ended 2022, and we have informed the Pakistan Stock Exchange in this regard.

Further, the term of our existing directors who were elected on 21st May 2020 under Section 161 of the Companies Act 2017, will expire on 21st May 2023. In view of this, the Company will have to convene an additional General Meeting specifically for the Election of Directors.

Therefore, the Company proposes to hold the Annual General Meeting on May 22, 2023, in order to hold the Election of the Directors along with the Annual General Meeting.

2. Whereas every listed company is required to hold its annual general meeting within one hundred and twenty (120) days after the end of the financial year in accordance with Regulation No. 5.7.1 of the PSX, and to submit its financial statements before the said meeting. Also, in accordance with Regulation No. 5.6.9(a) of the PSX, the Company is required to send/transmit to the Exchange, its statutory report, annual report containing therein the audited financial statements, auditors' report, directors' report and the chairman's review report, not later than twenty one (21) days before the meeting of the shareholders.



GlaxoSmithKline
Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi – 74000,
Pakistan

T +92 21 111 475 725

Since, the Financial Statements for the year ended December 31, 2022 will also be adopted in the Annual General Meeting, which is proposed to be held on May 22, 2023, therefore, we shall be obliged if the Company is permitted to also transmit the Annual Report accordingly as per the requirement of 21 days' notice period.

Further, please note that the Financial Statements for the first quarter ending March 31, 2023 will be finalized in time according to the law and will be published and transmitted in time to the Exchange.

It is, therefore, humbly requested prayed that keeping in view the circumstances, we may kindly be granted extension for 30 days to hold the Annual General Meeting and present the audited balance sheet and profit and loss account for the year ended 31 December, 2022 under section 132 and 223 of the Companies Act, 2017, as per revised timeline.

Thanking you.

Yours faithfully,

**For and on behalf of
GlaxoSmithKline Pakistan Limited**


**Ms. Mehar-e-daraksha Ameer
Company Secretary**

Encl: 1. Copy of printed Annual Report of 2021
2. Affidavit duly signed by the Company Secretary
3. Paid Challan of Rs.15,000/-

c.c. Ms. Rahat Wajid
Joint Registrar
Company Registration Office
Securities & Exchange Commission of Pakistan
4th Floor, SLIC Building No.2, Wallace Road
Karachi

Mr. Hafiz Maqsood Munshi
Manager
Companies & Securities Compliance – RAD
Pakistan Stock Exchange
Stock Exchange Building
Stock Exchange Road
Karachi



SECP Challan

M-2023-506713

01

Bank Branch	KARACHI, MCB - Uni Tower[1105]	Date	16-03-2023
Account Title	Securities and Exchange Commission of Pakistan	Account No.	0183089871000097
Name of Company	GLAXO SMITHKLINE PAKISTAN LIMITED	Registration No.	0000061

Receipt under Companies Act, 2017

Code No.	Head of Accounts	Amount (Rs)
61051	Registration Fee for New Incorporation	
61053	Filing Fee	
61055	Mortgages / Charge Registration	
61054	Additional Filing Fee	
61056	Availability of Name Fee	
61057	Copying Fee	
61058	Inspection Fee	
61059	License Fee - U/S 42 / Renewal Fee	
61060	Application Fee	
61063	Application for extension in AGM	
61052	Enhancement of Capital Fee (Form - 7)	
61061	Appeal/Complaint Fee	
61064	Application for Capital issue U/S 86	
61063	Application for extension in AGM	15000.00
24071	CLD Penalty	
24075	Penalty imposed by Enforcement	
61060	Annual Fee payable by an Inactive Company u/s 424	
61060	Annual Renewal Fee under for Free Zone Companies u/s 454	
61060	Application for change of Name u/s 11 and 12	
61060	Application Fee for Petition u/s 32	
61060	Application for conversion of status of the Company u/s 46,, 47, 48 and 49	
61060	Application for Issuance of Shares at discount u/s 82	
61069	Annual Fee for Inactive Companies U/S 424	
61070	Data Sharing (Banks) Fee	
52403	Bank Collection Charges (To Be Paid By Applicant)	25.00
Total		15025.00

Payment Details	
Cheque No.	621668
Drawn On	STANDARD CHARTERED
Rupees (in words)	Fifteen Thousand Twenty Five Rupees Only
Name of Depositor	FAISAL IQBAL
Depositor Signature	Teller Signature & Bank Stamp

Original



- Payment may kindly be deposited in the bank within a month of the date appearing in date column of challan.
- Photocopy of the challan shall not be entertained, kindly print separate challans for each company/ Form.
- Cutting and erasing of any field on challan is not allowed.
- Challan number and amount of money deposited must be clearly legible on a printed challan.
- If system erroneously generates a challan without company name or challan No. then kindly do not deposit that challan into bank and contact concerned CRO.



SECP Challan

M-2023-506713

01

Bank Branch	KARACHI, MCB - Uni Tower[1105]	Date	16-03-2023
Account Title	Securities and Exchange Commission of Pakistan	Account No.	0183089871000097
Name of Company	GLAXO SMITHKLINE PAKISTAN LIMITED	Registration No.	0000061

Receipt under Companies Act, 2017

Code No.	Head of Accounts	Amount (Rs)
61051	Registration Fee for New Incorporation	
61053	Filing Fee	
61055	Mortgages / Charge Registration	
61054	Additional Filing Fee	
61056	Availability of Name Fee	
61057	Copying Fee	
61058	Inspection Fee	
61059	License Fee - U/S 42 / Renewal Fee	
61060	Application Fee	
61063	Application for extension in AGM	
61052	Enhancement of Capital Fee (Form - 7)	
61061	Appeal/Complaint Fee	
61064	Application for Capital issue U/S 86	
61063	Application for extension in AGM	15000.00
24071	CLD Penalty	
24075	Penalty imposed by Enforcement	
61060	Annual Fee payable by an Inactive Company u/s 424	
61060	Annual Renewal Fee under for Free Zone Companies u/s 454	
61060	Application for change of Name u/s 11 and 12	
61060	Application Fee for Petition u/s 32	
61060	Application for conversion of status of the Company u/s 46,, 47, 48 and 49	
61060	Application for Issuance of Shares at discount u/s 82	
61069	Annual Fee for Inactive Companies U/S 424	
61070	Data Sharing (Banks) Fee	
52403	Bank Collection Charges (To Be Paid By Applicant)	25.00
Total		15025.00

Payment Details	
Cheque No.	621668
Drawn On	STANDARD CHARTERED
Rupees (in words)	Fifteen Thousand Twenty Five Rupees Only
Name of Depositor	FAISAL IQBAL
Depositor Signature	Teller Signature & Bank Stamp



Applicant Copy

- Payment may kindly be deposited in the bank within a month of the date appearing in date column of challan.
- Photocopy of the challan shall not be entertained, kindly print separate challans for each company/ Form.
- Cutting and erasing of any field on challan is not allowed.
- Challan number and amount of money deposited must be clearly legible on a printed challan.
- If system erroneously generates a challan without company name or challan No. then kindly do not deposit that challan into bank and contact concerned CRO.



STAMP OFFICE CITY CO URT, KARACHI

Issued to M. A. Khan

CNIC/LEG No. _____

Vide D.S.R.No. 299 Dt: 29.7.22

For the Purpose of _____

On Cash _____

Ex Office Vendor

29 JUL 2022



AFFIDAVIT

I, Mehar-e-Daraksha Ameer D/o Ameer Ali Chandio, Muslim, adult, resident of Flat No. 906, Abeeda Tower, Civil Lines, Karachi, Company Secretary of GlaxoSmithKline Pakistan Limited solemnly declare as under:

1. That I am the Company Secretary of GlaxoSmithKline Pakistan Limited.
2. That I am fully conversant with the affairs of the Company.
3. That whatever has been stated in the accompanying application submitted under Section 132 of the Companies Act, 2017 is true and correct to the best of my knowledge and belief.
4. That noting has been concealed in this respect.



Deponent

Solemnly affirmed before me at Karachi this _____ day of _____ 2023 by the deponent above named who is personally known to me.



SWORN BEFORE ME
SYED NASIR HUSSAIN
ADVOCATE & OATH COMMISSIONER
KARACHI, PAKISTAN

17 MAR 2023